Action GENOMIC HEALTH, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Genomic Health, Inc.

Actions

US37244C1018

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Genomic Health : Stockholders Approve Proposed Acquisition by Exact Sciences
PR
Genomic Health : New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
PR
Genomic Health : New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
PR
WeissLaw LLP Investigates Genomic Health, Inc.
PR
Genomic Health : Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
PU
Genomic Health : Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
PU
Genomic Health : to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
PR
Genomic Health : German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test
PR
Genomic Health : to Present at the Jefferies 2019 Healthcare Conference
PR
Genomic Health : Reports First Quarter 2019 Financial Results and Recent Business Progress
PR
Genomic Health : to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
PR
Genomic Health : New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test
PR
Genomic Health : Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance
PR
Genomic Health : to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019
PR
Genomic Health : Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
PR
Genomic Health : Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
PR
Genomic Health : NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
PR
Genomic Health : to Present at the 37th Annual J.P. Morgan Healthcare Conference
PR
Genomic Health : Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race
PR
Genomic Health : and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action
  4. Actualités Genomic Health, Inc.
  5. Communiqués